who should not take glp 1 medications Guidance from the MHRA, published in June 2025, on weightloss medication If you're in your 40s

Idiopathic intracranial hypertension, polycystic-ovary syndrome, and thrombophilia

Individual variation in GLP-1 receptor expression and gastrointestinal motility explains why one person tolerates a dose easily while another experiences significant symptoms at the same level

Enhanced AMPA Receptor Trafficking Mediates the Anorexigenic Effect of Endogenous Glucagon-like Peptide-1 in the Paraventricular Hypothalamus

Only 10% of patients on semaglutide lost 10% of their body weight in Verus Phase 2b

2024 Jun 26;13(13):3729

3094 in the Eastern District of Pennsylvania, where claims involving Mounjaro, Trulicity, Ozempic, Wegovy, and Rybelsus are proceeding together for pretrial purposes